去势抵抗性前列腺癌中AR-V7的作用机制及其相关治疗  

Mechanism of AR-V7 and its associated therapies in castration-resistant prostate cancer

作　　者：史伟 王玮 张敏 李庆元 SHI Wei;WANG Wei;ZHANG Min;LI Qingyuan(Department of Urology,Yantai Affiliated Hospital of Binzhou Medical University,Yantai,Shandong,264000,China;Department of Urology,Zibo Maternity and Child Health Care Hospital;Department of Urology,Jinan People’s Hospital;Department of Urology,Affiliated Hospital of Guilin Medical University)

机构地区：[1]滨州医学院烟台附属医院泌尿外科,山东烟台264000 [2]淄博市妇幼保健院泌尿外科 [3]济南市人民医院泌尿外科 [4]桂林医学院附属医院泌尿外科

出　　处：《临床泌尿外科杂志》2020年第8期661-664,共4页Journal of Clinical Urology

摘　　要：前列腺癌是全球男性生殖系统最常见的恶性肿瘤之一,同时也是男性肿瘤的主要死亡原因之一,近些年随着AR抑制剂阿比特龙以及恩杂鲁胺等药物的广泛应用,去势抵抗性前列腺癌(CRPC)的发病率也呈抬头趋势,本文就雄激素受体剪接变异体(AR-Vs)中的AR-V7的研究现状及其与AR抑制剂、紫杉烷类药物、AR-V7抑制剂的联系和CRPC治疗的研究新进展作一综述,为CRPC的治疗提供新的思路。Prostate cancer(PCa)is one of the most common malignant tumors in the male reproductive system worldwide.It is also one of the leading causes of death in male tumors.In recent years,with the widespread application of AR inhibitors abiraterone and enzalutamide,the incidence of castration-resistant prostate cancer(CRPC)is also on the rise.The current status of AR-V7 in androgen receptor splice variants(AR-Vs)and its relationship with AR inhibitors,taxanes and AR-V7 inhibitors were reviewed.Also,we reviewed the new advances in CRPC therapy so as to provide new ideas for the treatment of CRPC.

关 键 词：去势抵抗性前列腺癌 AR-V7 AR抑制剂 紫杉烷 AR-V7抑制剂 

分 类 号：R737.25[医药卫生—肿瘤]